{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T01:54:51Z","timestamp":1769565291994,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Convenio de Investigaci\u00f3n. Dep. de Salut. Generalitat de Catalunya","award":["352\/05"],"award-info":[{"award-number":["352\/05"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.jneuroim.2015.12.015","type":"journal-article","created":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T12:46:01Z","timestamp":1451479561000},"page":"73-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients"],"prefix":"10.1016","volume":"291","author":[{"given":"Elisabet","family":"Matas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Mart\u00ednez-Iniesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Romero-Pinel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Alba","family":"Ma\u00f1\u00e9-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Cobo-Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Mart\u00ednez-Y\u00e9lamos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2015.12.015_bb0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/jir.1998.18.345","article-title":"Development of neutralizing antibodies in patients with relapsing\u2013remitting multiple sclerosis treated with IFN-beta1a","volume":"18","author":"Antonelli","year":"1998","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/jnnp.73.2.148","article-title":"Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory","volume":"73","author":"Bertolotto","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0015","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1212\/01.WNL.0000046662.03894.C5","article-title":"Persistent neutralizing antibodies abolish the interferon \u03b2 bioavailability in MS patients","volume":"60","author":"Bertolotto","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jneuroim.2007.06.006","article-title":"IFN\u03b2 bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays","volume":"189","author":"Capra","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0025","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.55.8.671","article-title":"EDMUS, a European database for multiple sclerosis","volume":"55","author":"Confavreux","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jneuroim.2004.08.006","article-title":"Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis","volume":"158","author":"Gilli","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0035","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1177\/1352458506070941","article-title":"Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients","volume":"12","author":"Gneiss","year":"2006","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0040","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1212\/WNL.0b013e3181b04c98","article-title":"Absence of MxA induction by interferon \u03b2 in patients with MS reflects complete loss of bioactivity","volume":"73","author":"Hesse","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0045","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/01.wnl.0000257128.53775.62","article-title":"Multiple sclerosis: relating MxA transcription to anti-interferon-beta-neutralizing antibodies","volume":"68","author":"Hoffmann","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0050","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0055","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0060","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1212\/01.WNL.0000129265.73259.9E","article-title":"Neutralizing antibodies reduce the efficacy of beta-IFN during treatment of multiple sclerosis","volume":"62","author":"Malucchi","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0065","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1212\/01.wnl.0000304040.29080.7b","article-title":"Predictive markers for response to interferon therapy in patients with multiple sclerosis","volume":"70","author":"Malucchi","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0070","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00415-010-5844-5","article-title":"One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients","volume":"258","author":"Malucchi","year":"2011","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.jneuroim.2015.12.015_bb0075","doi-asserted-by":"crossref","first-page":"e112758","DOI":"10.1371\/journal.pone.0112758","article-title":"Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients","volume":"9","author":"Matas","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0080","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jim.2005.11.011","article-title":"Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort","volume":"310","author":"McKay","year":"2006","journal-title":"J. Neuroimmunol. Methods"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0085","first-page":"17","article-title":"MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity","volume":"7","author":"Pachner","year":"2003","journal-title":"Mol. Diagn."},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0090","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis","volume":"352","author":"PRIMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0095","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ana.10290","article-title":"Assessment of different treatment failure criteria in a cohort of relapsing\u2013remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials","volume":"52","author":"R\u00edo","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0100","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ana.20224","article-title":"Defining interferon beta response status in multiple sclerosis patients","volume":"56","author":"Rudick","year":"2004","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2015.12.015_bb0105","doi-asserted-by":"crossref","first-page":"e94794","DOI":"10.1371\/journal.pone.0094794","article-title":"MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients","volume":"9","author":"Serana","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/jnnp.2007.122549","article-title":"In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralizing antibodies is titre-dependent","volume":"79","author":"Sominada","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0115","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(03)14541-2","article-title":"Clinical importance of neutralizing antibodies against interferon beta with relapsing\u2013remitting multiple sclerosis","volume":"362","author":"Sorensen","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0120","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/187153009787582379","article-title":"Interferon-beta therapy monitoring in multiple sclerosis patients","volume":"9","author":"Sottini","year":"2009","journal-title":"Edocr. Metab. Immune Disord. Drug Targets"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0125","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing\u2013remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial","volume":"43","author":"The IFNB Multiple Sclerosis Study Group","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0404.2007.00968.x","article-title":"MxA protein assay for optimal monitoring of IFN-b bioactivity in the treatment of MS patients","volume":"118","author":"Valittu","year":"2008","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2015.12.015_bb0135","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1515\/CCLM.2010.263","article-title":"Transfer of myxovirus-protein-A mRNA assay for interferon-\u03b2 bioactivity measurement in multiple sclerosis patients to routine laboratory practice. A 4-year experience","volume":"48","author":"Zanotti","year":"2010","journal-title":"Clin. Chem. Lab. Med."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815301089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815301089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:27:14Z","timestamp":1759048034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572815301089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":27,"alternative-id":["S0165572815301089"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.12.015","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}